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Introduction 
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INTRODUCTION: 
Thyroid hormone is essential for normal development. In humans they 
play a vital role in maintenance of metabolic functions and also on 
functioning of other organ systems. Iodine is the main content of thyroid 
hormone which is acquired by food intake. The thyroid gland contains large 
stores of thyroid hormone in the form of thyroglobulin. These stores regulate 
the level of hormone in system in spite of variations in availability of iodine 
and its intake
1
. 
Thyroid abnormalities are very common. Nodules, thyroid enlargement, 
and goitre are commonly encountered conditions which may be benign or 
malignant. Mostly in these conditions hormone levels in circulation will be in 
reference range. Thyroid hormone changes, both hyper and hypothyroidism 
are mostly associated with predominant clinical manifestations. Mild stage of 
disease will be presenting often with subtle clinical situation, which is 
confirmed by atypical laboratory tests. New born screening has been done 
now in developed countries for congenital hypothyroidism, so that early 
institution of appropriate hormone replacement therapy is given which has 
reduced mental retardation and cretinism due to hormonal deficiency.  
Hypothyroidism is a condition characterized by abnormally low thyroid 
hormone production. They are the common endocrine disorders with 
prevalence of 4-15% in world. In Indian adults the prevalence hypothyroidism 
was less than 10%. A study done in Cochin revealed prevalence of 
hypothyroidism as 3.9%. Also there was high prevalence of subclinical 
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hypothyroidism with 9.4%.Women: Men prevalence in that study was 11.4% 
and 6.2% respectively
1
. 
 Thyroid hormones are necessary for normal development of organs. 
Overactive thyroid ending up in increased release of T3 and T4 in 
bloodstream ends up in thyrotoxicosis. Hypothyroidism is the reverse 
condition. Primary hypothyroidism is due to problem in thyroid gland itself 
while secondary hypothyroidism is due to inadequate functioning of 
“hypothalamic-pituitary-thyroid-axis”. Iodine deficiency is the commonest 
global reason of hypothyroidism. 
Hypothyroidism is a common condition and harmful effects are caused 
on cardiovascular system both by overt and subclinical hypothyroidism
2
. This 
is caused by several different mechanisms which cause increased risks of 
atherosclerosis and coronary heart disease
3, 4
. 
A number of inflammatory biomarkers in circulation are related with 
increased risk of acute coronary syndrome. They may give an idea about 
various pathways involved in progression of disease and act as an important 
tool for predicting cardiovascular events and atherosclerosis
5
. Secretory 
Phospholipase A2 group 2A (PLA2G2A) is one of such inflammatory marker 
for atherosclerosis, which is a chronic inflammatory condition and 
Adiponectin, which is a hormone derived from adipose tissue is proven to 
have anti-inflammatory and anti-atherogenic effects. Only very few studies 
were available on hypothyroidism and inflammation and no study was 
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conducted on inflammatory markers- PLA2G2A and Adiponectin with 
hypothyroidism in India. 
This study was done to compare the status of inflammation in 
hypothyroidism with these inflammatory markers and also to explore the 
possible relationship between hormonal replacement and the differences in 
risk of atherosclerosis and related markers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aims & Objectives 
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AIMS & OBJECTIVES: 
PRIMARY OBJECTIVE: 
To identify the possible relationship between hormone treatment and 
the risk of atherosclerosis in hypothyroid patients. 
 
SECONDARY OBJECTIVE: 
To explore the status of inflammation with respect to PLA2G2A and 
Adiponectin in hypothyroid patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature 
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REVIEW OF LITERTURE: 
The thyroid is named for the Greek word for “shield shaped”, from the 
shape of the nearby tracheal cartilage. It was initially given importance when 
enlargement of thyroid gland associated with changes in the eyes and the heart 
was observed which is we now name as hyperthyroidism. Parry saw his first 
patient in 1786 but did not publish his findings until 1825. Graves reported the 
disorder in 1835 and Basedow in 1840. Hypothyroidism was described later, 
in 1874, when Gull linked atrophy of thyroid gland with the signs typical of 
hypothyroidism. Myxedema as a term was first used for a clinical syndrome 
which has typical thickening of subcutaneous tissue which was due to 
increased mucus formation in 1878 by Ord. In 1891, Murray first treated a 
hypothyroidism case by injecting sheep thyroid gland extract, which was 
found to be fully effective when given by mouth. The successful treatment of 
thyroid deficiency by administering thyroid extract was an important step 
toward modern endocrinology.  
Later Gley‟s study on parathyroid glands in the late 19th century 
proved the variation of these two endocrine glands functionally. The structure 
of parathyroid hormone, however, was not reported until the early 1970s. 
Calcitonin was discovered in 1961, demonstrating that the thyroid gland 
produced a hormone in addition to thyroxine
6
. 
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Anatomy: 
The thyroid which is a latin word which means thyreos as shield, and 
eidos means form i.e. in form of shield. It contains two lobes which is 
connected by an isthmus. Anatomically it is situated to anterior of trachea 
between cricoid cartilage and suprasternal notch. Normally it‟s about 12-20 g 
with soft consistency and high vascularity. Parathyroid hormone is produced 
by four parathyroid glands. They are situated posterior to thyroid. On the 
lateral borders there is recurrent laryngeal nerves which should be noted 
during thyroid surgery to avoid injury resulting in vocal cord paralysis
7
. 
Embryological development of thyroid gland is from the floor of the 
primitive pharynx which develops during the third week of gestation. The 
gland moves along the thyroglossal duct to reach the neck. Synthesis of 
thyroid hormone begins normally around 11 weeks of gestation. The thyroid 
gland consists of numerous spherical follicles which contains follicular cells 
that surround secreted colloid, a proteinaceous fluid containing very high 
levels of thyroglobulin, precursor of thyroid hormones
8
. 
 
Physiology: 
Thyroxine (T4) and triiodothyronine (T3) are the hormones formed on 
thyroglobulin, which is produced within thyroid cell. It is a glycoprotein. 
When inorganic iodide enters the follicular cell of thyroid it gets oxidized by 
thyroid peroxidase after which it covalently bound to tyrosine residues of 
thyroglobulin. 
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• The residues of tyrosine gets iodinated into 2 forms 
monoiodotyrosine (MIT) and diiodotyrosine (DIT). They undergo coupling 
under catalytic activity of thyroxine peroxidase to form thyronines. Two DIT 
forms T4 and one MIT and one DIT together form T3. 
• Release of hormones into circulation is influenced by proteolysis 
which happens inside cells of thyroid. Hormonal transport occurs through 3 
plasma proteins in bloodstream namely 
 Albumin 
 Thyroid binding pre-albumin and  
 Thyroid binding globulin 
Physiological effect mainly happens through free unbounded form of 
hormone which also regulate the secretion of TSH from pituitary by negative 
feedback mechanism. 
• Among both T3 and T4, the secretion of T4 is exclusively from the 
gland, whereas T3 only 20% is from gland while bulk of T3 is from the T4. 
This T4 gets breakdown into T3, the step is catalysed by 5'-monodeiodinase. 
Tri iodothyronine (T3) is 5 times more active than T4. 
• T4 may produce reverse T3 by the enzyme 5'-monodeiodinase, it has 
no important physiological activity. 
• Thyroid hormone production is regulated by Thyroid Stimulating 
Hormone (TSH) secreted by anterior lobe of pituitary gland. Through 
negative feedback mechanism TSH controls the level of Free T3 and T4 in 
bloodstream, also helpful in influence of hypothalamic TRH. Production of 
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hormone and its release is mainly controlled through deiodination of T4 to T3 
extracellularly. This control can be influenced by drugs, illness, nutrition and 
other hormones
9
. 
 
Chemistry of Thyroid Hormones: 
The main hormones of thyroid gland are T3 and T4. Based on the 
composition of hormones it was initially assumed that the activities of thyroid 
was due to contents in thyroxine (T4). Further studies on this aspect revealed 
basic preparations of hormone had more calorigenic action than that could 
have been due to thyroxine. Then aroused the discussion on a “second” 
hormone which lead to identification of T3. It was identified, secluded, and 
produced by Gross and Pitt-Rivers (1952). Triiodothyronine has a much 
higher affinity for the nuclear thyroid receptor compared with thyroxine (T4) 
andis much more potent biologically on a molar basis. The subsequent 
identification of T3 production from T4 in thyreotic humans led to the 
practice of effective replacement with levothyroxine alone in 
hypothyroidism
10
. 
Structure - Activity Relationships: 
The structural component required for a significant degree of thyroid 
hormone activity has been defined. Coming to the potency the mono 
compound are much potent than di-substituted counterpart. Hence T3 is 5 
times highly effective than thyroxine, and 3‟-isopropyl-3, 5-DIT is 7 times 
additionally effective in its function. Substitutions at the 3, 5, 3‟, and 5‟ sites 
influence the conformation of the molecule. In thyroxine, structurally angle 
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between 2 rings at ether O2 is120°, and along the axis they rotate freely. The 
presence of 3, 5 iodines restrict rotation of the two rings. In general, the 
binding of iodothyronines to the thyroid hormone receptors (TRs) parallels 
their biological potency, but additional factors can modify therapeutic 
potency, including affinity for plasma proteins, metabolic rate, and rate of 
entry into nuclei. Specific thyroid hormone transporters, like MCT8, are 
important in specific tissues
11
. 
Figure 3.1 Chemistry of thyroid Hormone
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The stereo chemical nature of the thyroid hormones plays an important 
role in determining hormone activity. Many analogues of T4 are produced to 
confirm this SAR, also to know the hormone‟s antagonists and to investigate 
chemical structure have required activity without adverse effects. Introduction 
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of specific aryl methyl groups at the 3‟ position of triiodothyronine results in 
analogues that are liver-selective, cardiac sparing thyromimetics
12
. Solving 
the X-ray crystallographic shape of domains binding to ligands of the nuclear 
thyroid hormone receptors α and β has resulted in the rapid development of a 
range of TR isoform-selective compounds. The difference in the ligand 
binding domain region between TRα and TRβ is only a single amino acid (Ser 
277 in TRα and Asn 331 in TRβ). GC-1, a TRβ-specific agonist, stabilizes the 
ligand binding domain by promoting hydrogen bonding between Asn331 and 
Arg282. GC-1 has a 10-fold greater affinity for TRβ, the predominant TR 
isoform in the liver, than TRα, the predominant TR isoform in the heart, and 
lowers cholesterol without stimulating the heart. Cholesterol lowering with 
cardiac sparing by GC-1 and other TRβ-selective agonists, however, is also 
the result of much higher distribution in the liver and less in the heart 
compared with T3. Similar compounds, such as KB-141, lower cholesterol in 
clinical studies
11
. Interestingly, none of these newer thyroid hormone analogs 
contains iodine or any halogen. 
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Figure 3.2 Mechanism of Thyroid Hormone Receptor 
Action
46
 
 
Biosynthesis of Thyroid Hormones
13-24
 
 The production of thyroid hormones is exclusive and complicated 
mechanism. The thyroid hormones are synthesized and stored in 
thyroglobulin. It is a protein which contains most of the colloid of thyroid 
follicle as residues of amino acid
13
. The gland is capable of keeping more 
amount of hormone by this method, and a notable part of thyroid mass 
constitutes extracellular thyroglobulin. It is a multifaceted glycoprotein 
having 2 indistinguishable units, both of 330,000 Da. Interestingly; molecular 
cloning has demonstrated that thyroglobulin belongs to a super family of 
12 
 
serine hydrolases, including acetylcholinesterase. The normal mechanism of 
synthesis, storage, release, and conversion of thyroid hormones are as follows: 
    
Figure 3.3 Thyroid Hormone Biosynthesis and Release
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The above process is explained in below figure. 
 
Figure 3.4  Thyroid Hormone Biosynthesis and Release
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1. Iodide uptake: From diet, the iodine in form of iodide ion (I–) reaches 
circulation. Normally, iodine level in the plasma is too low (0.2-0.4 μg/dL; 
15-30 nM), but the thyroid gland actively transports the ion via a specific 
membrane-bound protein, NIS. As a result this effective transport against the 
gradient, the ratio of thyroid to plasma iodide concentration is usually 
between 20 and 50 and can exceed 100 in the active gland. The iodide 
transport mechanism blocked by many agents like perchlorate and 
thiocyanate. Thyrotropin (thyroid-stimulating hormone [TSH]) stimulates NIS 
gene expression and promotes insertion of NIS protein into the membrane in a 
functional configuration. 
Thus iodide uptake increased by decreased stores of thyroid iodine, and 
decreased by the administration of iodide by NIS protein expression. NIS has 
been identified in other tissues, including salivary glands, gastric mucosa, 
small intestine, choroid plexus, skin and perhaps placenta; all of these organs 
sustain a level of iodide greater than that of the blood. Iodide accumulated in 
the placenta and mammary glands provide adequate supplies for the foetus 
and infant. Accumulation of Iodine throughout the body is mediated by a 
single NIS gene. Individuals with congenital NIS gene mutations have absent 
or defective iodine concentration in all tissues known to concentrate iodine. 
 
2. Oxidation and Iodination. Consistent with the conditions generally 
necessary for halogenations of aromatic rings, the iodination of tyrosine 
residues requires the iodinating species to be in a higher state of oxidation 
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than is the anion. The iodinating species is hypoiodite, either as hypoiodous 
acid or as an enzyme-linked species. 
The oxidation of iodide to its active form is accomplished by thyroid 
peroxidase, a heme-containing enzyme that uses hydrogen peroxide (H2O2) as 
the oxidant. The peroxidase is membrane bound and appears to be 
concentrated at or near the apical surface of the thyroid cell. The reaction 
results in the formation of monoiodotyrosyl and diiodotyrosyl residues in 
thyroglobulin just prior to its extracellular storage in the lumen of the thyroid 
follicle. The formation of the H2O2 that serves as a substrate for the 
peroxidase probably occurs near its site of utilization and is stimulated by a 
rise in cytosolic Ca2+. The receptor to TSH is notably promiscuous in its 
coupling, motivating adherents of 4 G protein families including Gq, which 
couples to the PLC-IP3-Ca2+ pathway; thus, a Ca2+-dependent effect on 
H2O2 production may be a means by which TSH stimulates the organification 
of iodide in thyroid cells. 
 
3. Formation of Thyroxine and Triiodothyronine from Iodotyrosines. The 
remaining synthetic step is the coupling of two diiodotyrosyl residues to form 
thyroxine or of monoiodotyrosyl and diiodotyrosyl residues to form 
triiodothyronine. These oxidative reactions apparently are catalyzed by the 
same thyroid peroxidase. The mechanism involves the enzymatic transfer of 
groups, perhaps as iodotyrosyl free radicals or positively charged ions, within 
thyroglobulin. Although many other proteins can serve as substrates for the 
peroxidase, none is as efficient as thyroglobulin in yielding thyroxine. 
16 
 
Presumably, conformation of thyroglobulin facilitates this coupling reaction. 
Thyroxine formation primarily occurs near the amino terminus of the protein, 
whereas most of the triiodotyrosine is synthesized near the carboxy terminus. 
The relative rates of synthetic activity at the various sites depend on the 
concentration of TSH and the availability of iodide. Iodine deficiency is 
associated with an increase in thyroidal T3 relative to T4 content. 
Because triiodothyronine is the transcriptionally active iodothyronine 
and contains only three-fourths as much iodine, a decrease in the quantity of 
available iodine need have little impact on the effective amount of thyroid 
hormone elaborated by the gland. Although a decrease in the availability of 
iodide and the associated increase in the proportion of monoiodotyrosine       
favour the formation of triiodothyronine over thyroxine, a deficiency in 
diiodotyrosine ultimately can impair the formation of both compounds. Intra 
thyroidal and secreted T3 are also generated by the 5‟-deiodination of 
thyroxine. 
 
4. Resorption; 5. Proteolysis of Colloid; and, 6. Secretion of Thyroid 
Hormones. Because T4 and T3 are synthesized and stored within 
thyroglobulin, proteolysis is main chunk of secretory method. This process is 
started by endocytosis of colloid from the follicular lumen at the apical 
surface of the cell, with the participation of a thyroglobulin receptor, megalin. 
This “ingested” thyroglobulin appears as intracellular colloid droplets, which 
apparently fuse with lysosomes containing the requisite proteolytic enzymes. 
For hormones to be released thyroglobulin should be broken down in 
17 
 
particular composition as required by the hormones to be get to released. The 
MW of thyroglobulin is 660,000 Da, and the protein is made up of 300 
carbohydrate residues and 5500 AA residues, only 2-5 of which are thyroxine; 
thus this is an extravagant process. TSH enhances the degradation of 
thyroglobulin by increasing the activity of several thiol endopeptidases of the 
lysosomes. Endopeptidases selectively cleave thyroglobulin, yielding 
hormone-containing intermediates that subsequently are processed by 
exopeptidases. The liberated hormones then exit the cell, presumably at its 
basal membrane. When the TG is hydrolyzed, MIT & DIT also released but 
usually they doesn‟t leave from gland; rather, gets selectively metabolized and 
the iodine, liberated as I–, is reincorporated into protein. The iodotyrosine 
deiodinase enzyme, DHAL1, is essential for conserving iodine and mutations 
of this gene identified in several kindred‟s are associated with goitrous 
hypothyroidism and cognitive deficit. When there is intensive activation of 
proteolysis by TSH these iodine gets reused, rest reaches blood, sometime 
along with iodotyrosines. 
 
7. Thyroid Hormone Metabolism and Conversion of Thyroxine to 
Triiodothyronine in Peripheral Tissues. The normal production of thyroxine 
is estimated to range between 80 and 100μg/day; that of triiodothyronine is 
between 30 and 40μg. Although triiodothyronine is secreted by the thyroid, 
metabolism of thyroxine by 5‟, or outer ring, deiodination in the peripheral 
tissues accounts for ~80% of circulating triiodothyronine. In contrast, removal 
of the iodine on position 5 of the inner ring produces the metabolically 
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inactive 3, 3‟, 5‟-triiodothyronine (reverse T3, rT3). Under normal conditions, 
~40% of T4 is converted to each of T3 and rT3, and ~20% is metabolized by 
other pathways, such as glucuronidation. Normal level of T4 in plasma is 4.5-
11 μg/dL; those of T3 are ~1/100 of that (60-180 ng/dL). The types 1 and 2 
deiodinases (D1, D2) convert thyroxine to triiodothyronine. These enzymes 
contribute approximately equally to the plasma T3 in rats, but it has not been 
possible to determine their relative contributions in humans. D1 is expressed 
primarily in the liver and kidney, and also in the thyroid and pituitary. It is up 
regulated in hyperthyroidism and down regulated in hypothyroidism. A 
clinically important feature of D1 is its inhibition by the anti-thyroid drug 
propylthiouracil. D1 is localized to the plasma membrane, and the T3 it 
produces equilibrates rapidly with the plasma. D2 is present principally in 
CNS and adipose tissue mainly brown, also in the thyroid, and at very low 
levels in other organs such as skeletal muscle. The activity of D2 is unaffected 
by propylthiouracil. D2 localizes to the endoplasmic reticulum, which 
facilitates access of D2-generated T3 to the nucleus. Hence organs that 
express D2 tend to use the locally generated T3 to increase the occupancy of 
nuclear T3 receptors, and D2-generated T3 equilibrates slowly with the 
plasma. D2 is dynamically regulated by its substrate, thyroxine, such that 
elevated levels of the enzyme are found in hypothyroidism and suppressed 
levels is found in hyperthyroidism. Thus, D2 autoregulates the intracellular 
supply of triiodothyronine in organs in which it is expressed. Inner ring- or 5-
deiodination, the main inactivating pathway of T3 metabolism, is catalyzed 
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mainly by the type 3 deiodinase (D3), and to some extent also by D1. D3 is 
found at highest levels in the CNS and placenta, and it also is expressed in 
skin and uterus. It is highly expressed in hemangiomas. D3 can be induced at 
sites of inflammation, and at least in an animal model this can result in local 
hypothyroidism. 
D2 and D3 also play important roles in regulating local T3 levels during 
development, during which thyroid hormone tends to promote differentiation 
and decrease proliferation. Examples include chondrocyte development and 
bone differentiation, and auditory (cochlea) development. In the brain, D2 is 
expressed in glial cells and D3 in neurons.  
Because T3 receptors are enriched in neurons, the current model is that 
glial cells convert T4 to T3, which is then exported and taken up by neurons 
where it activates T3 receptors, with subsequent degradation by D3 and 
termination of the T3 effect. There is a growing recognition of circumstances 
where D2 and D3 regulate local thyroid hormone levels independent of the 
plasma T4 and T3 concentrations. The three deiodinases contain the rare 
amino acid selenocysteine in their active sites. Incorporation of selenocysteine 
into the growing peptide chain is a complex process involving multiple 
proteins. Mutations in one such protein, SECIS binding protein 2, are 
associated with abnormal circulating thyroid hormone levels. 
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Transport of T3 and T4 Hormones in the Blood: 
Iodine is normally present in several forms, with 95% as organic iodine 
and ~5% as iodide. Most organic iodine is thyroxine (90-95%); 
triiodothyronine represents a relatively minor fraction (~5%). The hormones 
are moved into circulation by a non-covalent solid link with plasma 
proteins
22
.TBG is an important transporter of T3 & T4. It is an acidic 
glycoprotein with a molecular mass of ~63,000 Da that binds one molecule of 
T4 per molecule of protein with a very high affinity (the equilibration 
dissociation constant, Kd, is ~10
-10
 M). T3 is bound less avidly. Thyroxine, 
but not triiodothyronine, also is bound by transthyretin (thyroxine-binding 
prealbumin), a retinol-binding protein. This protein is present in higher 
concentration than is TBG and primarily binds thyroxine with an equilibrium 
dissociation constant ~10
-7
 M. Transthyretin has four apparently identical 
subunits but only a single high-affinity binding site. Albumin also can bind 
thyroxine when the more avid carriers are saturated, but it is difficult to 
estimate its quantitative or physiological importance except in familial 
dysalbuminemic hyperthyroxinemia. It is an AD disorder with increased 
affinity of albumin for thyroxine, the reason behind this is point mutation in 
gene encoding albumin. There are a number of genetic defects of thyroid-
binding globulin
22, 23
, but these individuals generally have normal circulating 
free thyroid hormones and serum TSH, and they are euthyroid. The free 
(unbound) hormone is a small percentage (~0.03% of thyroxine and ~0.3% of 
triiodothyronine) of the total hormone in plasma. The differential binding 
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affinities for serum proteins also contribute to establishing the 10- to 100-fold 
differences in circulating hormone concentrations and half-lives of T4 and T3. 
Essential to understanding the regulation of thyroid function is the “free 
hormone” concept: Only the unbound hormone has metabolic activity. Thus, 
because of the high degree of binding of thyroid hormones to plasma proteins, 
changes of plasma level of hormone may affect the affinity to their proteins.  
Certain drugs and a variety of pathological and physiological conditions, such 
as the changes in circulating concentrations of estrogens during pregnancy or 
during the administration of oral estrogens, can alter both the binding of 
thyroid hormones to proteins and the amounts of these proteins. However, 
because the pituitary responds to and regulates circulating free hormone 
levels, minimal changes in free hormone concentrations are seen. Therefore, 
laboratory tests that measure only total hormone levels can be misleading. 
Degradation and Excretion: Thyroxine is eliminated slowly from the body, 
with a t1/2 of 6-8 days. In patient with hyperthyroidism, the t1/2 is shortened 
to 3-4 days, whereas in patient with hypothyroidism it may be 9-10 days. 
These changes presumably reflect altered rates of metabolism of the hormone. 
In conditions associated with increased binding to TBG, such as pregnancy, 
clearance is retarded. The increase in TBG is due to the oestrogen-induced 
increase in the sialic acid content of the synthesized TBG, resulting in 
decreased TBG clearance. The opposite effect is observed when there is 
reduced protein binding of thyroid hormones or when binding to protein is 
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inhibited by certain drugs. T3, which is less avidly bound to protein, has a t1/2 
of around 1 day. 
The important site of degradation of hormones is liver; T4 & T3 
undergo glucronide conjugation and also sulfate conjugation ending up in 
biliary excretion. Some thyroid hormone is liberated by hydrolysis of the 
conjugates in the intestine and reabsorbed. A portion of hormone which has 
undergone conjugation is hydrolysed in colon and faecal excretion occurs. 
As discussed earlier, the important pathways of metabolism of T4 is 
deiodination into T3 or reverse T3. Triiodothyronine and reverse T3 are 
deiodinated to three different DIT, they are then deiodinated to two MIT, 
inactive forms which are usual constituents of human plasma.  
 
Regulation of Thyroid Function: Thyrotropin or TSH is a glycoprotein 
hormone with α and β subunits analogous to those of the gonadotropins. 
Normally TSH is released in circadian rhythm and pulsate pattern; with peak 
levels during sleep. Its secretion is mainly regulated by hypothalamus which 
releases TRH and in relevant to thyroid profile in blood stream. Excess 
hormone present inhibits transcription of gene for TRH and those for 
thyrotropin α and β subunit, it suppresses TSH secretion causing regression of 
thyroid
24
. When there is below normal level of hormone, the thyroid 
spontaneously increases the secretion of TSH. Additional mechanisms 
mediating the action of T3 and T4 on TSH seems to be due to reduction in 
TRH secretion by the hypothalamus and a reduction in the number of TRH 
receptors on pituitary cells. 
23 
 
 
 
          Fig 3.5 Regulation of thyroid hormone secretion
47
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Thyrotropin-Releasing Hormone: TRH stimulates the release of 
preformed TSH from secretory granules and also stimulates the subsequent 
synthesis of both α and β subunits of TSH. Somatostatin and glucocorticoids 
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at therapeutic doses inhibit TRH-stimulated secretion of TSH. The mature 
hormone is produced from protein that has 6 copies of the tripeptide attached 
to dibasic residues 
25
. 
TRH also has been localized in the CNS in the cerebral cortex, 
circumventricular structures, neurohypophysis, pineal gland, and spinal cord. 
These findings, as well as its localization in nerve endings, suggest that TRH 
may act as a neurotransmitter or neuromodulator outside of the hypothalamus. 
Administration of TRH to animals produces CNS-mediated effects on 
behavior, thermoregulation, autonomic tone, and cardiovascular function, 
including increases in blood pressure and heart rate. 
 TRH also has been identified in pancreatic islets, heart, testis, and parts 
of the gastrointestinal tract. Its physiological role in these sites is not known. 
Two TRH receptors have now been identified, TRH-R1 and TRH-R2, as well 
as selective analogs for these receptors
25
. TRH analogs with CNS activity, but 
without other hormonal actions, are being developed for therapeutic 
applications. TRH is no longer available in the U.S
26
. 
 
Actions of Thyroid-Stimulating Hormone: On administration of TSH in 
animals, the first measurable consequence on thyroid hormone metabolism is 
increased secretion, which is detectable within minutes. All phases of 
hormone synthesis and release are eventually stimulated: iodide uptake and 
organification, hormone synthesis, endocytosis, and proteolysis of colloid. 
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There is increased vascularity of the gland and hypertrophy and hyperplasia of 
thyroid cells. 
These effects follow the attachment of TSH and its receptor on thyroid 
cell plasma membrane. The TSH receptor is a GPCR that is structurally 
similar to the receptors for luteinizing hormone and follicle-stimulating 
hormone
26
. These receptors share significant amino acid homology and have 
large extracellular domains that are involved in hormone binding. Binding of 
TSH to its receptor stimulates the Gs-adenylyl cyclase–cyclicAMP pathway. 
Higher concentrations of TSH activate the Gq-PLC pathway. Both the 
adenylyl cyclase and the phospholipase-C signaling pathways appear to 
mediate action of TSH on functioning of thyroid in humans
27
. Germline 
mutations can present as congenital, non autoimmune hypothyroidism or as 
AD toxic thyroid hyperplasia
28
. Transmutations of the TSH-R can cause 
gestational hyperthyroidism due to a hypersensitivity of the receptor to 
HCG
29
. Somatic mutations that result in stimulation of the receptor are 
associated with increased activity of thyroid adenomas
30
. Finally, resistance to 
TSH has been described, both in families with mutant TSH receptors
31. 
 
Relation of Iodine with Thyroid Function: Sufficient iodine intake is 
required for routine functioning of thyroid, when it is less there will be 
abnormality in functioning of thyroid and elevation in TSH levels results in 
enlargement of thyroid. As a result there will be increased extraction of 
thyroid, developing an iodine gradient that may be 10 times normal; in mild to 
moderate cases through this mechanism the deficiency is somewhat balanced 
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but in severe deficiency as this balance cannot be maintained, cretinism in 
children and hypothyroidism in adult occurs
32
. 
Regions of iodine deficiency exist in Central and South America, Africa, 
Europe, Southeast Asia, and China. In the U.S., recommended daily 
allowances for iodine range from 90-120 μg for children, 150μg for adults, 
220 μg for pregnancy, and 290 μg for lactation33. Vegetables, meat, and 
poultry contain minimal amounts of iodine, whereas dairy products and fish 
are relatively high in iodine. The success of many experiments treatment led 
to the adoption of iodine prophylaxis and therapy in many regions throughout 
the world where iodine-deficiency goiter was endemic
20,33
. 
The most practical method in substituting iodide or iodate is by table 
salt; iodate is now preferred. The use of iodized salt is required by law in 
some countries, but in others such as the U.S., the use is optional. In the U.S., 
iodized salt provides 100 μg of iodine per gram. Although the U.S. population 
remains iodine sufficient, iodine intake has steadily decreased over the last 20 
years
34,35
. The most recent data indicate that iodine intake has stabilized, 
although pregnant women remain a susceptible population for iodine 
insufficiency
35
. Other vehicles for supplying iodine to large populations who 
are iodine deficient include oral or intramuscular injection of iodized oil, 
iodized drinking water supplies, iodized irrigation systems, and iodized 
animal feed
36,37
. 
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Actions of Thyroid Hormones: 
 
Classical Nuclear-Mediated Effects: It is mediated largely by attachment of 
T3 to TRs belonging to nuclear superfamily
38,39
. They also consist of 
receptors for,  
 Vitamin D 
 Steroid hormones 
 Fatty acids 
 Retinoic acid 
 Bile acid 
The nuclear receptor superfamily also includes a number of “orphan 
receptors” that have no known ligands and may be regulated by post 
translational modifications or other events. The TRs have the classic nuclear 
receptor structure
39
. 
T3 binds to TRs with 10-fold greater affinity than does T4, and T4 is not 
thought to be biologically active in normal physiology. TRs bind to specific 
DNA sequences (TREs) in the promoter/regulatory regions. The transcription 
of most target genes is repressed by unliganded TRs and induced following 
the binding of T3. The mechanisms of these effects have been well studied
39
. 
In the unliganded state, the TR ligand binding domain interacts with a co-
repressor complex that includes histone deacetylases and other proteins. The 
binding of T3 causes replacement of the co-repressor complex by a co-
activator complex that includes histone acetyltransferases, methyltransferases, 
and other proteins. The actual situation is very complex and probably involves 
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cyclical recruitment of multiple protein complexes to the target gene, leading 
to cyclical transcription despite the constant presence of T3
40,41
. Rest are 
negatively regulated by T3. The mechanism is not well defined, but these 
genes tend to be induced by the unliganded TR in addition to being repressed 
by T3. 
The TRs are the cellular homologs of the avian retroviral oncoprotein c-
erbA. There are two genes that encode TRs, THRA and THRB. THRA encodes 
the receptor TRα1. The biological function of TRα1 is inferred largely 
through studies of genetically modified mice and cell culture experiments 
because human mutations in THRA have not been described. Although TRα1 
is expressed in most cell types, studies in knockout mice demonstrate that the 
major specific roles for this isoform are in the regulation of heart rate, body 
temperature, skeletal muscle function, and the development of bone and small 
intestine
41. Alternative splicing of the TRα primary transcript results in the 
production of TRα2, which does not bind T3 because it lacks part of the 
ligand binding domain (LBD). TRα2 is expressed ubiquitously and its 
function is unknown, although there is some evidence that it may inhibit T3 
action. A cryptic promoter within intron 7 of THRA drives the production of 
small proteins that contain only a portion of the TRα LBD. These non-
hormone-binding proteins appear to play a role, along with TRα1, in GI 
development. 
The THRB gene has two promoters that lead to the production of TRβ1 
and TRβ2. These receptors have unique amino terminal domains but 
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otherwise are identical. TRβ1 is ubiquitous, whereas TRβ2 has a highly 
restricted pattern of expression. Mutations in THRB cause the syndrome of 
resistance to thyroid hormone. Studies in these patients, as well as in 
genetically modified mice and in cell culture, demonstrate a specific role for 
TRβ1 in liver metabolism (including the hypocholesterolemic effect of T3), 
and for TRβ2 in the negative feedback by T3 on hypothalamic TRH and 
pituitary TSH
43. TRβ2 also is important in the development of cones in the 
retina and in inner ear development. 
Non-genomic Effects of Thyroid Hormone
44
: Although nuclear receptors 
were classically described as being DNA-binding transcription factors, it is 
now clear that these proteins also can be found outside the nucleus where they 
can exert biological effects via rapid non genomic mechanisms
48
. TRs 
associate in a T3-dependent manner with the p85α subunit of phosphatidyl 
inositol 3-kinase (PI3K), which results in the phosphorylation and activation 
ofPKB/Akt
45
. The PI3K/Akt pathway has broad effects on cellular 
metabolism. For example, it stimulates NO production by endothelial cells, 
which leads to vasodilation. Hence, T3 administration causes rapid 
vasodilation. There also is evidence for non-genomic actions of thyroid 
hormone via a plasma membrane receptor within integrin αVβ3. This putative 
receptor binds extracellular T4 in preference to T3, resulting in activation of 
MAP kinase. However, the importance of non-genomic actions in thyroid 
hormone physiology and pathophysiology remains uncertain. 
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Effects of Thyroid Hormone Metabolites: 3-Iodothyronamine and 
thyronamine, naturally occurring metabolites of T4, are ligands for the GPCR 
trace amine associated receptor 1 (TAAR1)
49
. Administration of 3-
iodothyronamine or thyronamine to mice causes hypothermia and 
bradycardia, presumably through activation of TAAR1 and Gs. 3-
Iodothyronamine activation of TAAR1 also induces insulin secretion in the 
MIN6 cell line
50
. Interestingly, 3-iodothyronamine also binds to the α2A 
adrenergic receptor, leading to decreased insulin secretion from mouse islets 
via a Gi protein coupled mechanism. The importance of these effects in 
human physiology and disease remains to be determined. 
 
Major Clinical Effects of Thyroid Hormones: 
Growth and Development: Perhaps the most dramatic example of thyroid 
hormone action is amphibian metamorphosis, in which the tadpole is almost 
magically transformed by triiodothyronine into adult frog. They also have a 
main part in development of brain
51,52
. If such hormones are not available 
during the first 6 months after birth it may cause cretinism with mental 
abnormalities, abnormal development of brain structure will also ensue. The 
main reasons for these changes are problem in projection of axon, synapticity 
and problem in migration of neuron. So it‟s better to give a minimal dose for 
two wks at least to high risk babies to avoid any such abnormalities. 
The mechanisms by which thyroid hormone promotes brain 
development are incompletely understood. Surprisingly, mice with genetic 
deletions of TRα,TRβ, or both have essentially normal brain development53. 
31 
 
Equally surprisingly, genetic deletion of TRα1 protects mice from the toxic 
effects of hypothyroidism on brain development. Perhaps it is the effects of 
unliganded TRs that result in impaired brain development, such that either T3 
or the absence of TRs is protective. T3 induces the expression of a number of 
genes that could plausibly be important in normal brain development, but the 
exact roles of these specific gene inductions are not known
51
.  
The T3-dependent expression of many proteins appears to be merely 
delayed in the hypothyroid animal; normal levels are eventually 
achieved.RC3/neurogranin, a protein involved in synaptic plasticity, also is 
induced by T 3. Through its induction of the transcription factor BTEB (basic 
transcription element binding protein), T3 expands a network of secondary 
genes in brain development. 
The actions of thyroid hormones on protein synthesis and enzymatic 
activity are not limited to the brain, and in fact most tissues are affected by the 
administration of thyroid hormone or by its deficiency. The extensive defects 
in growth and development in cretins vividly illustrate the pervasive effects of 
thyroid hormones in normal individuals. 
 
Cretinism is of two types: 
1. Sporadic 
2. Endemic 
Endemic cretinism is mostly seen in places where endemic goiter is 
present, main cause is severe deficiency of iodine.  
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Sporadic type is due to failure of normal development of thyroid or 
defective synthesis of hormone. In case of synthesis defect goiter may be 
present. 
 
Figure 3.6 Symptoms of Cretinism 
 
 
For an active management early diagnosis should be made before 
appearance of clear signs and symptoms. In region of endemic cretinism, for 
pregnant women earlier iodine replacement should be started so that when it is 
given up to 2
nd
  trimester there will better development of brain and also 
psychologically for the infants
54,99
. Concentrations of TSH and thyroxine are 
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measured in blood from the umbilical cord or from a heel stick. The incidence 
of congenital dysfunction of the thyroid is 1 per 4000 births. 
Thermogenic Effects: Thyroid hormone is necessary for both obligatory 
thermogenesis (the heat resulting from vital processes) as well as for 
facultative or adaptive thermogenesis
55
. Obligatory thermogenesis is the result 
of T3 making most biological processes thermodynamically less efficient for 
the sake of producing heat. Multiple mechanisms underlie the stimulation of 
obligatory thermogenesis, but the pathways involved and their quantitative 
contributions have yet to be fully defined. The ability of T3 to induce the 
skeletal muscle Ca++-dependent ATPase (SERCA1) contributes to 
thermogenesis by stimulating the cycling of calcium between cytosol and 
sarcoplasmic reticulum.  
Metabolic “futile cycling" (e.g., lipogenesis-lipolysis) has been 
considered a mechanism to produce heat, but best estimates indicate the 
contribution is minor. Other than in brown adipose tissue, there is no evidence 
that a major thermogenic mechanism is uncoupling of phosphorylation, 
although some groups still believe that T3 can increase the proton leak 
through the inner mitochondrial membrane. Regardless of the mechanism, 
thermogenesis is highly sensitive to thyroid hormone around the physiological 
range because small changes in L-thyroxine replacement doses may 
significantly alter resting energy expenditure in the hypothyroid patient. The 
discovery of type 2 deiodinase in brown fat and its activation by the 
sympathetic nervous system showed that thyroid hormone also is important 
34 
 
for facultative thermogenesis. The ability of T3 to stimulate thermogenesis 
has evolved along with ancillary effects to support this thermogenic action, 
such as the stimulation of appetite and lipogenesis. 
 
Cardiovascular Effects: Obvious changes are seen in heart and related 
structure in both hyper- and hypothyroidism
56
. Hyperthyroid patients have 
tachycardia, augmented SV, CI greater than before, LVH, amplified PP and 
diminution in PVR. Hyperthyroidism is a relatively common cause of atrial 
fibrillation. Hypothyroid patients have decrease in HR and cardiac index, 
pericardial effusion, augmented PVR, diminuted  PP and increase in MAP. 
Triiodothyronine directly regulates myocardial gene expression 
primarily through TRα1, which is expressed at a higher level in 
cardiomyocytes than TRβ. T3 shortens diastolic relaxation (lusitropic effect) 
by inducing expression of the sarcoplasmic reticulum ATPase SERCa2 and 
decreasing phospholamban, a SERCa2 inhibitor. T3 increases the force of 
myocardial contraction (inotropic effect) in part by inducing expression of the 
ryanodine channel, the calcium channel of the sarcoplasmic reticulum. T3 
induces the gene encoding the myosin heavy chain (MHC) α isoform and 
decreases expression of the MHC β gene. Because MHCα endows the myosin 
holoenzyme with greater ATPase activity, this is one mechanism by which T3 
enhances the velocity of contraction. The chronotropic effect of T3 is 
mediated by increases in the pacemaker ion current if in the sinoatrial node. 
Several proteins that comprise the If channel are induced by T3, 
includingHCN2 and HCN4. The vasodilation effect on SM by direct action of 
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T3 is sometime present, which may contribute to the decreased systemic 
vascular resistance and increased cardiac output of hyperthyroidism. 
 
Metabolic Effect: They also increases presence of low-density lipoprotein 
LDL-R and the also metabolises bile acids from cholesterol, hence increase in 
cholesterol levels is important feature of hypothyroidism. Thyroid hormone 
has complex effects on carbohydrate metabolism
57
. Thyrotoxicosis is an 
insulin-resistant state. In addition, the rate of glucose absorption from the gut 
is increased. Compensatory increases in insulin secretion result in 
hyperinsulinemia. There may be impaired glucose tolerance or even clinical 
diabetes, but most hyperthyroid patients are euglycemic. However, diabetic 
patients already on insulin may have increased insulin requirements in the 
setting of hyperthyroidism. On the other hand, there will be decrease in 
glucose absorption, along with reduction in secretion of insulin. Glucose 
metabolism generally is not affected in a clinically significant manner in non-
diabetic patients, although insulin requirements decrease in the hypothyroid 
patient with diabetes. 
 
Pathophysiology of hypothyroidism: 
 
Aetiology of 1º Hypothyroidism includes, 
1. Hashimoto‟s disease - an autoimmune condition 
2. Iatrogenic hypothyroidism 
3. Iodine deficiency 
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4. Enzyme defects 
5. Hypoplasia of Thyroid gland  
6. Goitrogens 
7. Family H/O hypothyroidism100 
 
Aetiology of 2º Hypothyroidism includes, 
1. Surgery 
2. Tumours 
3. Radiotherapy 
4. TB 
5. Autoimmune disease 
6. Sheehan‟s syndrome 
7. Histiocytosis 
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Figure 3.7 Clinical Features of Hypothyroidism
46
 
 
 
 
Diagnosis: 
• Thyroid profile test  
 Serum TSH - increased 
 FT4 - sometimes normal initially 
 As the disease progresses, FT4 reduces less than normal range 
38 
 
 T3 is often within normal range level.  
 Anti-peroxidase antibodies and anti-thyroglobulin antibodies are 
likely to be elevated. 
• Secondary hypothyroidism should be suspected in a patient with 
decreased levels of T4 and inappropriately normal or low TSH levels. 
 
Treatment of hypothyroidism: 
• Drug of choice –Levothyroxine 
Advantages: 
 Stable 
 Cheap 
 No antigenicity 
 Good potency. 
 Required dose based on body weight 1.6 µg/kg46,101. 
 For young patients with concomitant chronic illness 
 Patients > 45 yrs without known cardiac disease  
Starting dose is 50µg which can be raised up to 100µg daily 
• For patients > 45 yrs with cardiac condition 
 Starting dose daily – 25 mcg 
 Raised by 25 mcg every month 
• Adults – maintenance dose - 125µg/day 
• Levothyroxine can be given for pts with subclinical cases and elevated 
levels of Thyroid stimulating antibodies. 
•During Pregnancy - Levothyroxine  
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Main aim is to reduce TSH to 1 mIU/L  
 Drug influence on levothyroxine 
 Cholestyramine 
 CaCO3 
 Al2OH 
 FeSO4 and 
 Dietary fibre supplements 
These drugs have influence on absorption.  
• Drugs raising nondeiodinative T4 clearance  
 Rifampin 
 Carbamazepine 
 Phenytoin  
Amiodarone blocks the conversion of T4 to T3 
 
Thyroid, USP  
 Extracted from thyroid of sheep, beef 
 Antigenicity present 
 Bioequivalence is absent 
Thyroglobulin  
 Purified extract from hog-gland 
 Ratio of T4:T3 is 2.5:1 
 Not used much 
. 
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Liothyronine 
 Synthetic form of T3 
 Good potency  
 Higher cardiotoxicity 
 Costly 
 Follow up is difficult 
Liotrix  
 Synthetic form 
 T4:T3 ratio is 4:1 
 Stable chemically 
 Steady potency 
 Costly 
 
General effects due to hormone replacement: 
 Cardiac failure 
 Angina pectoris 
 Myocardial infarction 
 Allergic reactions  
 Reduced Bone mineral density 
 
Treatment of myxoedema coma: 
• Initial treatment 
          Levothyroxine 
Route: IV bolus, 300 µg to 500 µg 
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• Followed by Liothyronine IV 
• Hydrocortisone IV100 mg/TDS until adrenal suppression is ruled out. 
Recovery expected within 24 hours. 
• Maintenance dose is 75µg to 100 µg IV  
• Then continued by oral therapy 
• Supportive therapy may be required  
• Maintain BP, blood sugar, temperature, ventilation 
Evaluation of therapeutic outcomes: 
• Serum TSH levels -Sensitive and specific 
                                   Best value for dose adjustment. 
                                   Normally values gets corrected by 6 wks 
• Every six wks - TSH and T4 monitoring to be done. 
       Until normal reference range reaches. 
       If TSH is high - dose is not enough. 
       Serum T4 level useful in- 
1. Spotting malabsorption 
2. Non compliance 
3. Bioequivalence abnormalities 
 Serum TSH - identifies noncompliance. 
• If deficiency due to failure of pituitary or hypothalamus only way is 
replacement by throxine and monitoring it. 
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Atherosclerosis: 
    Atherosclerosis is mainly due to increased deposit of lipid plaques in the 
bigger vessels and its wall is one of the common causes of incidence of 
cardiovascular disease. The global occurrence is 11%, and occurrence 
standardized by age is 9.0%
58, 59
. It is more in patients with impaired glucose 
tolerance and DM compared to healthy group. In Indians there is basically 
low HDL level resulting in a premature CAD in Asian ethnicity. Similarly 
LDL is also on higher side in CAD compared to healthy people. But 
altogether even with minimal elevation of LDL associated with moderate 
increase in LDL/HDL and low HDL and also increase in TC:HDL ratio may 
lead to atherosclerosis. 
Though pathophysiology is yet to be assessed in detail atherosclerosis is 
thought to be stimulated by combination of multiple factors like condition of 
blood flow, deposition of lipoprotein in sub intima and its variation, and 
malfunction of endothelium. Disease progression is related to chronic 
inflammatory response which causes fibrosis, necrosis of tissue and finally 
thrombosis, since it‟s a chronic disease it is more important to observe the 
whole pathogenesis on trot which need a longer time of study. Dysfunction of 
endothelium is one of first and important indicator of atherosclerosis, and is 
commonly observed in prospective clinical studies and they appear even 
before clinical manifestation of the disease. 
Atherosclerostic plaque formation is the important and primary cause for 
CAD and ACS. Dysfunction of endothelium leads to the generation of fatty 
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streaks in the walls of the coronary arteries and then formation of 
atherosclerotic plaques. The cardiovascular complications develop mainly due 
to rupture, erosion or fissuring of an unstable plaque. The susceptible plaques 
usually have a thin fibrous cap, high fatty core, large number of inflammatory 
cells like macrophages and lymphocytes
60
.    
 
Figure 3.8 Chronic inflammation and atherosclerosis
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Evolution of Atheroma
62-65
: 
The endothelial cells which are attached to the blood in the lumen of the 
arteries are rested on the basement membrane. The elastic lamina situated 
internally forms the barrier between the tunica intima and media. The tunica 
media contains multiple layers of SM cells, packed tightly than in intima, 
embedded in a matrix which has abundant elastin and collagen. In early 
atherogenesis, inflammatory cell recruitment and lipid accumulation lead to 
development of lipid rich core leading to arterial enlargement. If inflammation 
and other risk factors persist, the lipid core grows, and proteinases secreted by 
the activated leukocytes degrade the ECM, while pro-inflammatory cytokines 
like IFNγ limit the production of new collagen. Above changes thin the 
fibrous cap and make it friable and liable to rupture. After rupture, blood 
coming in contact with the tissue factor in the plaque coagulates. Activation 
of platelets by thrombin generated from the coagulation cascade and by 
contact with the intimal compartment initiates the thrombus formation. If the 
thrombus is occluding the blood vessel continuously, it results in an acute 
myocardial infarction. A wound healing response which is triggered by 
thrombin generated during blood coagulation stimulates smooth muscle 
proliferation. PDGF released from activated platelets stimulates smooth 
muscle cell migration. TFG-b, also released from activated platelets, 
stimulates interstitial collagen production. This increased migration, 
proliferation and extracellular matrix synthesis by smooth muscle cells 
thickens the fibrous cap and causes further expansion of the intima, often now 
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in an inward direction, yielding constriction of the lumen. Stenotic lesions 
produced by the fibrosed plaque due to encroachment into the lumen will 
restrict the flow, especially during increased cardiac demand, leading to 
ischaemia, commonly provoking symptoms such as angina pectoris. 
Advanced stenotic plaques, which are more fibrous are less susceptible to 
rupture and renewed thrombosis. Lipid lowering can decrease the content of 
lipid and slow down the intimal inflammatory response, which in turn provide 
a more „stable‟ plaque with a thick fibrous cap and a preserved lumen. 
Figure 3.9 Evaluation of atherosclerosis
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Hypothyroidism and atherosclerotic risk factors
67
: 
Observational studies done previously have proven the idea that 
hypothyroidism accelerate atherosclerosis. A study showed that severe 
atherosclerosis was found in 84% myxedematous patients
68, 69
. Although 
controversy still exists, a meta-analysis showed that subclinical 
hypothyroidism is significantly associated with coronary heart disease at 
baseline and death from cardiovascular causes at follow-up
70
. However, it 
remains to be determined whether thyroxine replacement therapy reduces the 
risk of coronary heart disease in these patients. A study on the progression of 
coronary atherosclerosis in patients undergoing coronary angiography showed 
that treatment of hypothyroidism affected atherogenesis, although the number 
of patients enrolled was very small
71
. Nagasaki et al. showed that IMT 
inpatients with overt hypothyroidism was significantly higher compared with 
that in euthyroid control subject and 1-year treatment with levothyroxine 
reversed the increased IMT in hypothyroid
72
. 
Multiple studies clinically have proven that lot of factors are responsible 
and related to hypothyroidism like lipid abnormalities, dysfunction of 
endothelium, inflammation present chronically, insulin resistance and 
oxidative stress. Those studies also revealed these factors as a whole is not 
responsible and they interact between them and no factor is as effective alone 
 Hypercholesterolemia has been found to be one of the factors 
contributing for atherosclerosis. LDL is more susceptible to oxidation process 
which increases the atherogenicity in hypothyroid patients
73
. In addition HDL 
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concentration which is inversely related to atherosclerosis, was found to be 
decreased in hypothyroidism
74
. Therefore, the lipid profile in patients with 
overt hypothyroidism is generally prone to enhancement of atherosclerosis. 
Chronic inflammation is one of the factors which induce and stimulate 
atherosclerosis and related complications by having deleterious effects 
endothelium of blood vessels, this may be the reason due to which in 
hypothyroidism patients there may be increase in dysfunction of endothelium. 
Many mediators of inflammation like IL-6, TNF-α and CRP, are related to 
hypothyroidism. Interleukin - 6, is induced in preadipocytes by TSH which 
has harmful effects like atherosclerosis and damage to endothelium it is pro 
inflammatory cytokine. Another similar cytokine related with inflammation 
TNF-α has effect on NO activity. It damages activity of NO in endothelial 
cells .TNF alpha promotes oxidative stress which is a main facet of 
malfunction of endothelium, this is induced by TSH in bone marrow cells. 
Later it was proven that liver generated C reactive protein which is an acute 
phase protein is also linked with inflammation. It‟s was later identified to be 
an important marker which is having part in inflammation ending up in 
cardiovascular events. This CRP has a positive relation with TSH and in 
hypothyroidism patients appears to be elevated
86, 87
. 
Oxidant stress is an imbalance between oxidant and antioxidant 
substances, ROS, a family of molecules including hydroxyl radical, 
superoxide anion and their derivatives, exceed endogenous antioxidant 
defence mechanisms. Inflammation is one of the important causes of 
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oxidative stress as enzymatic systems produce a large amount of ROS, 
including xanthine oxidase and NADH/NADH phosphate oxidase induced by 
inflammatory stimuli. Since ROS reacts with NO readily, producing harmful 
reactive nitric intermediates, minimum oxidative stress in endothelial cells can 
uncouple NO synthesis and will be devastating to endothelial function. 
Induction of iNOS can therefore aggravate oxidative stress in inflammatory 
conditions. ROS can also impair endothelial function by activating NF-κB, 
which further increases the expression of inflammation-associated genes, and 
thus act as a negative feedback loop
88, 89
. 
Insulin resistance is associated with dyslipidemia, chronic inflammation 
and oxidative stress, which are aspects of metabolic syndrome. As mentioned 
above other three factors directly promote endothelial dysfunction, whereas 
insulin resistance is usually linked with metabolic syndrome with a minor 
direct action on endothelium. Metabolic syndrome has been taken as an 
important underlying cause for the majority of the cardiovascular diseases
90
.  
Endothelial dysfunction is generally accepted as an early step of the 
atherosclerosis. Measurement of flow-mediated endothelium-dependent 
vasodilatation
75 
indicated an association between hypothyroidism and 
atherosclerosis. A reduction in the availability of nitric oxide is suggested as 
the mechanism of endothelial dysfunction in hypothyroidism
76
. Few studies 
have proven that thyroid hormone replacement improved endothelial function 
in patients with hypothyroidism
77
. 
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Figure 3.10 Subclinical hypothyroidism induced endothelial dysfunction
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Hormones secreted by thyroid have various effects on vascular system 
and heart. Thyroid hormone (TH) exerts multiple effects on the heart and 
vascular system. Obvious hypothyroidism when present in association with 
hypertension and dyslipidaemia mostly ends up in CVD. Also if the patient is 
having subclinical hypothyroidism which presents with high TSH and normal 
T3 is an important indicator of MI and atherosclerosis. So it will be better to 
focus on this factor to find the interaction or relation between TSH and 
CVD
79,80
. 
Phospholipase A2 group 2A (PLA2G2A): 
Phospholipase A2 (PLA2) is an esterase that hydrolyzes membrane 
phospholipids at the sn2 position to generate free fatty acids like arachidonic 
acid and lysophospholipids. Arachidonic acid serves as a precursor for the 
synthesis of prostaglandins and leukotrienes. PLA2s are classified into three 
main families including the Ca2+ dependent secretory PLA2s, the cytosolic 
PLA2s, and the Ca2 + independent phospholipases. The phospholipaseA2 
group IIa (PLA2G2A) isoform belongs to the family of secretory PLA2 
(sPLA2). Elevated levels of PLA2G2A are observed in many diseases 
associated with inflammation including rheumatoid arthritis, pancreatitis, and 
septic shock. PLA2G2A contributes to the development of atherosclerosis. It 
not only acts on membrane phospholipids but also targets lipoproteins and 
dietary phospholipids. Consistent with its role in inflammation, PLA2G2A is 
expressed in macrophages, but it is also highly expressed in hepatocytes. 
Expression of the PLA2G2A gene is induced by cytokines including TNF α, 
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and IL-6. At the transcriptional level, PLA2G2A is stimulated by the nuclear 
factors NF-KB
81, 82
. 
  
Figure 3.11 Relation of Thyroid hormone and PLA2G2A
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A study was done in Tennessee, USA which showed that Thyroid 
hormone (T3) inhibits PLA2G2A transcription via binding of the T3 receptor 
(TR beta) and signifies that T3 regulates PLA2G2A expression and utilizes a 
novel mechanism of co repressor recruitment. Another study was done in Iran 
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in subclinical hypothyroid (SCH) patients to explore the possible association 
between SCH and the inflammatory marker PLA2G2A which showed a 
stronger association of SCH with PLA2G2A indicating that PLA2G2A is an 
inducer of inflammation
83
. There are very studies available regarding the 
association of PLA2G2A in development of atherosclerosis in 
hypothyroidism
84
. 
 
Adiponectin (ADP): 
ADP is a protein containing 244 AA constituting most copious gene of 
the adipose tissue, gene transcript 1. Almost 0.01% of total plasma proteins is 
occupied by ADP and range of plasma concentrations is five to thirty 
mg/ml
85
. 
There are 2 types of receptors for ADP (AdipoR), So far 1 and 2 is well-
known. Primary site of expression of AdipoR1 is muscle and that of AdipoR2 
is liver. ADP binds to AdipoR1 and AdipoR2 thereby causing increased 
glucose uptake followed by fatty acid oxidation in the skeletal muscle through 
AdipoR1, as a result reduced glucose output from the liver through 
AdipoR2
91
.  
 
There are 3 forms of circulation ADP  
 Trimer 
 Hexamer 
 HMW multimers 
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The physiological effects of ADP are mainly related to concentration in 
plasma, ADP isoforms with its related properties subtypes and its tissue-
specific expression. The most active form of ADP is the HMW
92
. They have 
different properties like  
 Anti-atherogenic 
 Anti-diabetic, and  
 Anti-inflammatory properties.  
          Many diseases are related to decreased levels of ADP such as 
1. Atherosclerosis 
2. Type 2 diabetes 
3. Low HDL 
4. Abdominal obesity 
5. Hypertension,  
6. Metabolic syndrome 
7. Hypertriglyceridemia 
 
Some biological actions of ADP acts together with thyroid hormones 
like reduction of body fat by increased thermogenesis and lipid oxidation, it is 
plausible that ADP may interrelate with thyroid axis
92
. These hormones are 
linked with insulin resistance, and association between ADP and thyroid 
hormones may present through direct or indirect communications between 
them. These hormones are prime controllers of metabolism of lipid and 
carbohydrate. Dysfunction of thyroid sometimes ends up in dyslipidaemia and 
diminishing of glucose metabolism. The reasons behind these abnormalities 
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are still unknown. The receptors were revealed to have important part in lipid 
and glucose metabolism. Abnormalities in these receptors causes rise in TGL 
content in tissue, leading to increased oxidative stress and inflammation 
which ends up in prominent glucose intolerance and insulin resistance. As the 
incidence of hypothyroidism increases with the age and body weight inverse 
relation in ADP level found in few studies.
97, 98 
 Many studies in animal with hypo or hyperthyroid state revealed 
debatable results about relation of thyroid hormones with ADP levels. Rats 
with hypothyroidism had different results with normal or increased levels of 
serum ADP. Another study revealed that response of ADP mRNA to changes 
in T3 levels depends on type and site of the White adipose tissue. Contrary to 
that, there was rise in ADP mRNA expression and release, while it was vice 
versa with methimazole in hypothyroid rats resulting in reduction in 
expression of ADP mRNA
93
. 
      Among few studies done in humans there were contradictory results on 
ADP and thyroid hormone interaction. A research was done in Turkey they 
analysed levels of ADP levels in women clinically identified as subclinical 
hypothyroidism also possible actions L-thyroxine on those levels. The study 
revealed that after L-thyroxine replacement for six months there was 
improvement in ADP levels which was not dependent on body fat mass
94
. 
Only very few studies were available on hypothyroidism and chronic 
inflammation and they were done in other parts of the world. Very few human 
studies were done on hypothyroidism and inflammatory markers PLA2G2A 
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and ADP. But they were also done as separate studies. Also no studies were 
found regarding the relationship between doses of thyroxine and its effect on 
inflammation. Though few similar studies have already done in other 
countries, ethnic variations, life style modifications and food habits differ in 
our country comparing to them. So we proposed this study to compare the 
status of inflammation in hypothyroidism with these inflammatory markers 
and also to explore the possible relationship between drug treatment and the 
risk of atherosclerosis
95, 96
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Methodology 
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METHODOLOGY: 
STUDY AREA: 
 PSG Hospitals, Coimbatore 
STUDY DESIGN: 
This study was a clinical prospective cross sectional study. After 
obtaining informed consent from the patients fulfilling the inclusion and 
exclusion criteria, samples of blood were collected, stored and data collection 
done during the same visit. 
STUDY POPULATION: 
Outpatients of General Medicine & Endocrinology Departments of 
PSG Hospitals  with clinical diagnosis of hypothyroidism. 
SAMPLE SIZE: 
  Prevalence of hypothyroidism around 4%, in South Indian Study (1) 
hence sample size based on formula 4 p q/d
2
 
  
= 4 X 4 X 96/ 25 = 61 
  Rounding off to 60 patients 
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        INCLUSION CRITERIA: 
Patients attending medicine OPD of age >18years with clinical 
diagnosis of hypothyroidism including old and new patients.  
EXCLUSION CRITERIA: 
1. Post operated and Radiation cases of thyroid are excluded 
2. Patients on Statins, Steroids, Metformin are excluded 
3. Age<18 years are excluded 
4. Those who on other system medication (ayurveda, siddha) 
ETHICAL APPROVAL: 
The proposal of study was accepted by institutional Human Ethics 
Committee (IHEC) preceding start of the study. The details and the purpose of 
the study protocol were explained to each participant individually and their 
doubts were clarified before obtaining informed consent. The informed 
consent forms were provided to the participants either in English or Tamil 
depending on the participant. The participants, who gave written informed 
consent and eligible for recruitment according to the inclusion criteria, were 
enrolled for the study. A copy of the consent form is attached in the annexure.  
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Tool used: 
 Data collection form 
 ELISA kit for analysis of PLA2G2A (CUSABIO PLA2G2A ELISA kit) and 
Adiponectin (RAY BIO Human Acrp30 ELISA kit) 
Sample collection and storage: 
Samples collected and separated using serum separator tube after 
allowing clotting for two hours at room temperature. Centrifugation done for 
15 minutes 1000 RPM then stored at -20°C. 
Analysis done: 
ECLIA test for TSH - from Biochemistry lab 
ELISA for PLA2G2A and Adiponectin - done  
Human Phospholipase A2 group 2A (PLA2G2A): 
PLA2G2A was estimated using CUSABIO PLA2G2A ELISA kit 
imported from USA. 
Methodology is through EIA to specify quantitatively estimated. A 
microplate with precoated Phospholipase A2 is used .Wells were kept and test 
and standard solution were added to those wells and PLA2 if present bind 
with the antibody (Ab). Then biotin layered Ab with high specificity for 
PLA2 is added, then avidin conjugated HRP was assay followed by substrate 
buffer. When colour develops the intensity is measured.  
59 
 
 
Level of Measurement (Range): 
1.56ng-100 ng per millilitres 
Storage: 
The ELISA kit was unopened and kept at 2-8 °C  
How reagent is prepared: 
After bringing the reagents to room temperature, freshly prepared 
standards are used. These standards should be used with in 4 hrs of 
preparation. Always distilled water should be used. 
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Figure 4.1 Reagent Preparation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Biotin-antibody (1x) vial was centrifuged before 
opening. It required a 100-fold dilution (10 μl of Biotin 
antibody + 990 μl of Biotin antibody Diluents) 
Centrifugation of the HRP- avidin (1x) vial was done 
before opening. It also required a100-fold dilution (10μl of 
HRP avidin + 990 μl of HRP-avidin Diluent) 
Wash buffer (1X) concentrate brought to room 
temperature.20 ml of Wash Buffer Concentrate (25 x) 
diluted with deionised water to prepare 500 ml of Wash 
Buffer (1 x) 
Standard vial centrifuged at 6000-10000rpm for 30s. Then 
reconstituted with 1 ml of Sample Diluent which produced a 
stock solution of 100 ng/ml. It was kept for 15 mins duration 
before making the dilutions 
250 μl of Sample Diluent pipetted into each tube (S0-S6). 
Stock solution was used to produce a 2-fold dilution series 
shown in the picture. Undiluted standard served as the high 
standard and Sample Diluent as the zero standard 
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Figure 4.2 Dilution series of sample 
 
 
 
 
 
 
 
 
 
 
 
 
Tube S7 S6 S5 S4 S3 S2 S1 S0 
ng/ml 100 50 25 12.5 6.25 3.12 1.56 0 
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Assay procedure: 
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Adiponectin: 
The Adiponectin was estimated using a ELISA kit named Ray Bio 
Human Acrp30 ELISA Kit, imported from Georgia, USA. 
Storage: 
Stored in deep freezer at -20ºC 
Figure 4.3 Preparation of Reagent: 
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Followed by: 
Figure 4.4 Serial Dilutions 
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Assay procedure: 
 
The plates were then inserted into an ELISA reader and the absorbance 
read. ELISA reader is a Bio-Rad system which is attached to a computer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
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RESULTS: 
 
Figure1. Age Distribution (in years) 
 
 
  
   Among the 60 patients included in our study, most of them 61.7%(37) 
were from 21 to 40 years of age, 28.3% (17) were from 41 to 60 years, with 
only 5% (3)patients in both ≤ 20 years and  > 61year age groups. 
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Figure 2. Sex Distribution (%) 
 
 
 
 
 
 
Among 60 patients 58 (96.7%) were female patients with only 2 
(3.3%) were male patients. 
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Figure 3. Body mass index (BMI) 
 
 
 
In our study 23 (38.3%) patients were overweight, while 22(36.7%) 
were of normal weight and 9 (15%) patients were obese with only 6 (10%) 
patients been underweight. 
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Figure 4. Marital status 
 
 
 
Among the 60 hypothyroid patients included in the study, 49(81.7%) 
patients were married and the remaining 11(18.3%) were unmarried. 
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Figure 5.Pregnancy status 
 
 
 
In our study group, among those 58 female patients recruited, 6 
(10.3%) patients were pregnant during the study period. 
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Figure 6.Family history 
 
 
 
Among the subjects included in our study, 26(43.3%) had a positive 
family history of hypothyroidism and the remaining 34(56.7%) patients had 
no other significant family history. 
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Figure 7.Duration of disease 
 
 
 
In our study group both the duration of the disease and the duration of 
treatment for hypothyroidism were found to be the same. 12 (20%) were 
newly diagnosed hypothyroid patients, 23(38.3%) were hypothyroid for less 
than 5 years while 25 (41.7%) were diagnosed with the disease since 5 years 
or more. 
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Figure 8.TSH values (mIU/L) 
 
 
 
Among the 60 hypothyroid patients, 36 (60%) had TSH value of less 
than 10, 12(20%) had between 11 to 25, with 8(13.3%) patients had between 
26 to 50, while only 4(6.7%) of them had more than 50. 
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Figure 9.Regular treatment 
 
 
 
 
Looking at the compliance of drug intake by the patients, among those 
48 hypothyroid patients who were on thyroxine treatment excluding the new 
onset patients, 42 (87.5%) were on regular treatment while the remaining 6 
(12.5%) were not on regular treatment. 
 
 
75 
 
 
Table 10.Disease duration & PLA2G2A 
 
Duration Number Mean SD 
0years(New) 12 7.00 4.15 
<5 years 23 8.15 4.54 
≥5years 25 8.81 3.68 
 
Figure 10.Disease duration & PLA2G2A 
 
 
The patients included in our study were divided into 3 groups based on 
the disease duration as new cases (0 years), <5years and ≥ 5 years and 
compared the PLA2G2A values of them. We analyzed using one way Anova 
test and the mean value was found to be higher among the patients with 
disease duration of ≥ 5 years in comparison to other 2 groups. There was no 
statistical significance among the groups (P value 0.46). 
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Table 11.Disease duration & Adiponectin 
 
 
 
 
 
                          Figure 11.Disease duration & Adiponectin 
 
 
 
The analysis of mean serum Adiponectin values among the 3 groups; 
i.e., new cases, with disease duration of < 5 years and ≥ 5 years found that the 
mean Adiponectin level was high in newly diagnosed hypothyroid patients 
followed by < 5 years duration and ≥ 5 years of duration with no statistical 
significant difference among the 3 groups by one way Anova test (P value 
0.66) 
Duration Number Mean SD 
0years(New) 12 4.81 1.32 
<5 years 23 4.09 2.34 
≥5years 25 3.53 2.18 
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Figure 12.Comparision of TSH & PLA2G2A 
 
 
 
The patients were divided into 3 groups based on their TSH values as ≤ 
25mIU/L, 26 to 50mIU/L and more than 50mIU/L and mean values 
PLA2G2A found to be increased. 
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Figure 13.TSH & Adiponectin (ADP) 
 
 
 
Similarly the mean values of adiponectin were found to decrease among 
the 3 groups when compared with the TSH values 
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Table 14.Throxine dose & PLA2G2A 
 
Dose (µg) Number Mean SD 
Not on drug 16 7.12 4.22 
Low dose 31 8.79 3.98 
High dose 13 8.08 4.28 
 
Figure 14.Throxine dose & PLA2G2A 
 
 
 
We analyzed the dose of thyroxine with that of serum PLA2G2A in our 
patients using one way Anova test and it was found that the mean was high in 
patients with low dose thyroxine followed by high dose thyroxine and there 
was no statistical significance (P value 0.44). 
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Table 15.Thyroxine dose & Adiponectin 
 
Dose Number Mean SD 
Not on drug 16 3.65 1.98 
Low dose 31 3.64 1.97 
High dose 13 4.72 3.24 
 
Figure 15.Thyroxine dose & Adiponectin 
 
 
 
When analyzed the relationship of thyroxine dose with that of serum 
Adiponectin levels using one way Anova test, though the mean was found to 
be higher in patients with high dose thyroxine as when compared to the 
patients on low dose thyroxine and those not on thyroxine but not of statistical 
significant difference (P value 0.31). 
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Table 16.Age of the patient & PLA2G2A 
 
Age Number Mean SD 
<30 22 7.25 4.01 
≥30 38 8.74 4.11 
 
Figure 16.Age of the patient& PLA2G2A 
 
 
 
When analyzed the serum PLA2G2A values with the age of the 
patients (below 30 years and above 30 years of age) using independent„t‟ test, 
the mean of PLA2G2A value was high in patients of age above 30 years 
compared to those below 30 with no statistical significant difference (P value 
0.17). 
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                Table 17.Age of the patient & Adiponectin 
 
Age (years) Number Mean SD 
<30 22 4.19 2.56 
≥30 38 3.74 2.25 
 
                             Figure 17.Age of the patient& Adiponectin 
 
 
 
We compared the age of the patients with serum adiponectin values 
using independent„t‟ test, though showed that the mean adiponectin level was 
high in patients less than 30 years compared to that of more than 30 years of 
age but not of statistical significant difference (P value 0.48). 
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Table 18.Body mass index (BMI) & PLA2G2A 
 
BMI Number Mean SD 
<25 30 7.95 4.09 
≥25 30 8.43 4.18 
 
Table 18.Body mass index(BMI) & PLA2G2A 
 
 
 
The comparison of BMI of the patients with that of PLA2G2A using 
independent „t‟ test values revealed that the value was high in patients with 
BMI of ≥ 25 compared to BMI of < 25 with no statistical significance (P 
value 0.65). 
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Table 19.Body mass index (BMI) & Adiponectin 
 
BMI Number Mean SD 
<25 30 4.44 2.47 
≥25 30 3.38 2.15 
 
              Figure 19.Body mass index (BMI) & Adiponectin 
 
 
 
The mean levels of serum adiponectin was high in patients with BMI 
<25 compared to patients with BMI ≥25 and analysis using independent „t‟ 
test showed no statistical significance (P value 0.08). 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
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DISCUSSION: 
This cross sectional study was done to explore the relationship between 
hypothyroidism and hormonal therapy with respect to chronic inflammation. 
It is mainly focused at identifying the plausible relationship between hormone 
treatment and the risk of development of atherosclerosis in patients with 
hypothyroidism and also aimed at exploring the status of inflammation with 
respect to PLA2G2A and Adiponectin in hypothyroid patients. 
 
The primary inclusion criteria of this study, was that all the patients 
who were attending Medicine or Endocrinology outpatient department of PSG 
hospitals with an age of more than 18 years with clinical diagnosis of 
hypothyroidism both the old and new hypothyroid patients were included and 
those patients with other active inflammatory drugs like Statins, Steroids, 
Metformin and who were on alternative medicines like ayurvedha, siddha etc. 
were excluded. This study also excluded the post operative and radiation cases 
of thyroid disorders.  
 
Sixty patients with diagnosis of hypothyroidism including both new and 
old patients were recruited. After obtaining written informed consent and 
patient‟s history, blood samples were collected, serum separated and stored at  
– 200 C. Then estimation of serum levels of both PLA2G2A and Adiponectin 
were done using ELISA kit. 
 
Out of sixty hypothyroid patients, 61.7% patients were from 21 to 40 
years of age, 28.3% were from 41 to 60 years of age. The number of patients 
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less than or equal to 20 years and more than 61 years were equal (5%) (Figure 
1). A study conducted in the South Indian population showed that 
hypothyroidism was more prevalent in the age group of 30-50(62%)
 97 
which 
is consistent with our study population. 
 
Among the 60 hypothyroid patients majority of them were females 
(96.7%) and only 3.3% of them were male patients (Figure 2).Similarly, 
another study from South India showed significantly higher proportion of 
females vs. males 
1 
with respect to the occurrence of hypothyroidism. 
 
 In this study, 10% patients were underweight with a BMI of less than 
18.5 kg/m
2
, patients with normal weight of BMI from 18.5 to 24.9 kg/m
2
 and 
overweight patients with BMI of 25 to 29.9 kg/m
2
 are almost equal 36.70% 
and 38.30% respectively.15% of patients were obese with a BMI of greater 
than or equal to 30 kg/m
2 
(Figure 3). A previous study done to ascertain the 
relationship between TSH and BMI revealed a significant relationship 
between serum levels of TSH and BMI. They demonstrated that there exists a 
parallel relationship i.e., mean TSH would increase as BMI increases 
85,98
. 
This study revealed the highest percentage of patients in the obese category, 
thus demonstrating the existence of relationship between TSH and BMI. 
 
Among the 60 hypothyroid patients, 81.7% patients were married and 
the remaining 18.3% were unmarried (Figure 4). Regarding the pregnancy 
status, 10.3% patients were pregnant (Figure 5). A study was done to 
determine the prevalence of gestational hypothyroidism since maternal 
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thyroxine deficiency is associated with poor obstetric outcomes and mental 
retardation in the surviving neonate. The prevalence of hypothyroidism during 
pregnancy had been estimated to be 0.3% to 0.5%
54,99
.  
In this study group out of 60 patients, 43.3% patients had a positive 
family history of hypothyroidism and the remaining 56.7% patients had no 
significant family history (Figure 6). A retrospective study was done to 
investigate the rationale for administering levo thyroxine to young subclinical 
hypothyroid patients which revealed that only positive family history seemed 
to influence the decision to initiate levo thyroxine therapy
100
. Thus in 
initiation of the treatment for patients newly diagnosed with hypothyroidism, 
the family history esteemed to play a vital role in management. 
On comparing the duration of treatment among all included patients, 
both the duration of the disease and the duration of treatment for 
hypothyroidism were found to be unified, indicating that all patients were 
mandate to be started on treatment even at the amid of diagnosis. Out of 60 
patients, 20% were found to be newly diagnosed hypothyroid patients, 38.3% 
were diagnosed of hypothyroidism less than 5 years and 41.7% were presenting 
with disease for5 years or more (Figure 7).  
In this study, among the 60 hypothyroid patients, 80% had TSH of ≤ 
25mIU/L, 13.3% between 26 to 50mIU/L and 6.7% more than 50mIU/L 
(Figure 8). Though 36  patient‟s TSH were less than 10mIU/L, the decision of 
subclinical hypothyroidism could not be made, as it was earlier mentioned in a 
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study that T3 and T4 values are critical in deeming a patient to be in subclinical 
hypothyroidism unless otherwise the patient should be treated accordingly
79,80
. 
Out of 60 hypothyroid patients in this study 20% were newly diagnosed 
hypothyroid patients and the remaining 80% were known cases of 
hypothyroidism. Among the known hypothyroid patients who were on 
thyroxine treatment, 87.5% were on regular treatment while the remaining 
12.5% were not on regular treatment (Figure 9). 
One of the objectives of this study was to establish if any relationship 
exists between hypothyroidism and atherosclerosis with reference to the 
inflammatory markers PLA2G2A and Adiponectin. Hence patients were 
grouped based on the duration of the disease as newly diagnosed hypothyroid 
patients (Group 1), hypothyroidism for less than 5 years (Group 2) and those 
with hypothyroidism for greater than or equal to 5 years(Group 3) (Figure 10). 
As PLA2G2A is a marker of inflammation, it is expected to considerably rise 
as the duration of the disease increases. Here though we could establish a mean 
difference in the rise of PLA2G2A with reference to the duration of disease, 
(mean of  Group 1was 7.00±4.15, Group 2  was 8.15± 4.54 and Group 3 it was 
8.81± 3.68) there was no statistical significance among the 3 groups. Also there 
was no study done so far with regard to establishment of correlation between 
duration of hypothyroidism and PLA2G2A levels and we are aimed at doing 
so. The probable reason for non-accomplishment of statistical significance 
though difference was seen in mean values would be due to smaller sample 
size. 
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Whereas, when compared the Adiponectin which is also an 
inflammatory marker for atherosclerosis with that of disease duration, there 
was a rise in the mean value of Adiponectin in newly diagnosed hypothyroid 
patients, followed by patients with less than 5 years of disease duration and 
then by ≥ 5 years of duration of disease (Figure 11) (mean of Group 1was 
4.81±1.32, Group 2 was 4.09± 2.34 and Group 3 was 3.53±2.18).Few studies 
have shown that hypothyroidism reduced the levels of Adiponectin
93,97
. But in 
this study though there was a mean difference that was not of statistical 
significance among the three groups. 
This study also analyzed the level of TSH with respect to the 
inflammatory markers. In three groups of patients [Group 1- less than or equal 
to 25mIU/L, Group 2- 26 to 50 mIU/L and Group 3 - greater than 50mIU/L] 
based on the level of TSH, the mean of PLA2G2A in Group 1 was 7.24 mIU/L, 
Group 2 was 9.16 mIU/L and in Group 3 was 9.48 mIU/L (Figure 12). This 
evidenced that the level of PLA2G2A increased with an increase in TSH level. 
But there was no much difference in rise between group 2 and 3 because 
patients with higher TSH would be on higher dose of Thyroxine
67
. 
Similarly we compared the levels of Adiponectin with that of TSH level. 
Here the mean of Adiponectin in Group 1 was 4.35 mIU/L, Group 2 was 3.71 
mIU/L and in Group 3 was 3.63 mIU/L (Figure 13).In this Adiponectin level 
decreased as the TSH level increased. Few studies have shown that 
Adiponectin value decrease as the TSH increase 
97
. 
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As the main objective was to identify the possible relationship between 
hormone treatment and the risk of atherosclerosis in hypothyroid patients, they 
were divided into three groups as patients who were not on thyroxine, patients 
on low dose of thyroxine and those who were on high dose of thyroxine 
(required dose of thyroxine is 1.6µg/kg)
46,101
. The value of PLA2G2A for these 
patients found, that the mean was high in patients with low dose thyroxine 
(8.79 ±3.98) followed by high dose thyroxine (8.08± 4.28) and then by patients 
not on drug (7.12 ± 4.22) (Figure 14). High mean value in the low dose group 
may be due to the reason that the thyroxine dose would not have been adequate 
enough for them. But there was no statistical significance between the three 
groups. 
Similarly this study analyzed the value of Adiponectin with the 
thyroxine treatment same as that for PLA2G2A (Figure 15).Here also it was 
found that the mean was high in patients with high dose thyroxine (4.72±3.24) 
compared to low dose thyroxine (3.64±1.97) and patients not on thyroxine 
group (3.65±1.98) which suggested that the low dose group did not receive 
adequate amount of thyroxine. Also there was no statistical significance among 
the groups. There were no studies done regarding the influence of thyroxine 
dose on chronic inflammation. 
This study also analysed the serum PLA2G2A values with the age of the 
patients using independent„t‟ test, and  found that the mean of PLA2G2A value 
was high in patients of age above 30 years (8.74±4.11) compared to those 
below 30 (7.25±4.01)with no statistical significant difference (Figure 16). As it 
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is an inflammatory marker it has to rise as the age increases. But there were no 
study done previously comparing the age with that of PLA2G2A. 
 
Whereas, Adiponectin when compared with the age of the patients, the 
mean was high in patients less than 30 years (4.19±2.56) and low in age greater 
than 30 years (3.74±2.25) (Figure 17). There were few studies which proved 
that the Adiponectin value decrease as the age of the patient increase
97
.  
The comparison of BMI of the patients with that of PLA2G2A using 
independent „t‟ test values showed that the value was high in patients with BMI 
of ≥ 25 kg/m2 (8.43 ± 4.18) compared to BMI of < 25 kg/m2 (7.95 ± 4.09) 
(Figure 18) . There were no previous studies done on PLA2G2A and BMI. 
 Also the mean levels of serum Adiponectin was high in patients with 
BMI <25 kg/m
2
 (4.44 ±2.47) compared to patients with BMI ≥25 kg/m2 
(3.38±2.15) and analysis using independent „t‟ test showed no statistical 
significance (Figure 19). There were studies proving that Adiponectin plays a 
major role with regard to obesity. Its value decreases in overweight and obese 
patients
67,85
. 
Lack of statistical significance in this study may be due to small sample 
size and was done as a cross sectional study. Since few limitations pertaining to 
this study, further Randomised controlled trials with regular follow ups in a 
large scale of patients may overcome the limitations in future. 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
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CONCLUSION: 
 
 Only sparse literatures were available on hypothyroidism and chronic 
inflammation and most of them were done in the western countries. There were 
very less number of studies done on hypothyroidism and PLA2G2A in other 
parts of the world. Also few studies done on Adiponectin with hypothyroidism 
were contradicting to one another. 
 This study was proposed to be done as there were no combined studies done on 
inflammatory markers - PLA2G2A & Adiponectin with  hypothyroidism in 
India.Also this was the first study done to understand the relationship between 
doses of thyroxine and its effect on chronic inflammation. 
 This study revealed that when the duration of hypothyroidism increased, there 
was a rise in level of PLA2G2A and fall in level of Adiponectin suggesting a 
relationship between hypothyroidism and chronic inflammation. 
 This study also found that patients on inadequate dose of thyroxine had higher 
chance of developing atherosclerosis than compared to patients on adequate or 
higher dose of thyroxine explaining the need for adequate dose as prescribed in 
the patient diagnosed with hypothyroidism as replacement therapy based on 
their body weight. 
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Annexures 
ANNEXURE 9.1 ABBREVATIONS 
 
ADP - Adiponectin 
AD - Autosomal dominant 
CRP - C reactive protein 
CVD - Cardiovascular disease 
DIT - Diiodotyrosine  
D1 - Type 1 deiodinase 
D2 - Type 2 deiodinase 
EIA - Enzyme immune assay 
ECM - Extracellular matrix 
GPCR - G protein coupled receptor 
HCG - Human chorionic gonadotropin 
H2O2  - Hydrogen peroxide  
IMT - Intimal medial thickness 
IL 6 - Interleukin 6 
IFNγ - Interferon γ  
HDL - high density lipoprotein 
LDL - low density lipoprotein 
LVH - left ventricular hypertrophy 
MI - Myocardial infarction 
MIT - Monoiodotyrosine 
MCT8-Thyroid hormone cell-membrane transporter 
NO - Nitric oxide 
NIS - Sodium iodide symporter  
PDGF - Platelet derived growth factor 
PLA2G2A - Secretory Phospholipase A2 group 2A 
PVR - Peripheral vascular resistance 
ROS - Reactive oxygen species 
SM - Smooth muscle 
T3 - Triiodothyronine 
T4 - Thyroxine 
TSH - Thyroid stimulating hormone 
TRE - Thyroid hormone response element  
TRH - Thyrotropin releasing hormone 
TBG -Thyroxine-binding globulin  
TGFβ - Transforming growth factor beta  
TRs - Thyroid hormone receptors 
TRα - Thyroid hormone receptor alpha 
TRβ - Thyroid hormone receptor beta 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE 9.2 CASE PROFOMA 
 
 
LAB NO:                                 
 
HEIGHT:                    WEIGHT:                                BMI: 
 
AGE: 
 
SEX:                                                                               BP: 
 
PLACE: 
 
MARITAL STATUS:                             
 
PREGNANCY STATUS: 
 
COMPLAINTS: 
 
 
 
TREATMENT HISTORY: 
 
 
 
 
FAMILY HISTORY: 
 
 
 
LAB INVESTIGATIONS: 
 
 
TSH 
 
 
T3 
 
 
T4 
 
 
PLA2G2A 
 
 
ADIPONECTIN 
 
 
 
ANNEXURE 9.3 
 
PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
 
I, MUTHAMIZHVEENA. R,  am carrying out a study on the topic: CLINICAL PROSPECTIVE CROSS 
SECTIONAL STUDY TO EXPLORE THE RELATIONSHIP BETWEEN HYPOTHYROIDISM AND HORMONE 
THERAPY WITH RESPECT TO CHRONIC INFLAMMATION as part of my research project being carried out 
under the aegis of the Department of PHARMACOLOGY. 
 My research guide is: Dr.K.BHUVENESWARI, Professor and Head of the department, Pharmacology.  
The justification for this study is:  The purpose of the this study is to compare the status of inflammation 
in hypothyroidism with inflammatory markers and also to explore the possible relationship between drug 
treatment and the risk of atherosclerosis. 
The objectives of this study are:  
PRIMARY OBJECTIVE:  To identify the possible relationship between hormone treatment and the risk of 
atherosclerosis in hypothyroid patients. 
 SECONDARY OBJECTIVE: To explore the status of inflammation with respect to PLA2g2A and adiponectin in 
hypothyroid patients. 
Sample size:  60 
 
Study volunteers / participants are (specify population group & age group): Outpatients of  General Medicine & 
Endocrinology departments of  PSG Hospitals with clinical diagnosis of  hypothyroidism of age >18 years.  
Location: The study will be conducted in General Medicine & Endocrinology department of PSGIMSR 
Hospital. 
 
We request you to kindly cooperate with us in this study. We propose collect background information 
and other relevant details related to this study. We will be carrying out:  
 
Initial interview (specify approximate duration): 10 minutes.  
 
Health education sessions: Nil 
 
Clinical examination (Specify details and purpose): Nil 
 
Data collected will be stored for a period of fifteen years. We will / will not use the data as part of 
another study. 
 
Blood sample collection: Specify quantity of blood being drawn:  5 ml.  
 
No. of times it will be collected: 1 
 
Whether blood sample collection is part of routine procedure or for research (study) purpose:   
 Research purpose  
Specify purpose, discomfort likely to be felt and side effects, if any: Pain while pricking 
 
Whether blood sample collected will be stored after study period: No, it will be destroyed 
 
Whether blood sample collected will be sold:  No  
 
Whether blood sample collected will be shared with persons from another institution: No 
 
Medication given, if any, duration, side effects, purpose, benefits: Nil 
Benefits from this study: The prevalence of atherosclerosis has increased in India, hypothyroid patients 
are more prone for atherosclerosis there are no direct markers for the diagnosis for these patients.  
SPLA2 and adiponectin are markers for chronic inflammation and thyroxine has beneficial effect.   
Risks involved by participating in this study: No risks 
How the results will be used:  Clinical Meeting at PSG Hospitals 
                                                   Dr.MGR Medical University dissertation 
If you are uncomfortable in answering any of our questions during the course of the interview / 
biological sample collection, you have the right to withdraw from the interview / study at anytime. 
You have the freedom to withdraw from the study at any point of time. Kindly be assured that your 
refusal to participate or withdrawal at any stage, if you so decide, will not result in any form of 
compromise or discrimination in the services offered nor would it attract any penalty. You will continue 
to have access to the regular services offered to a patient. You will NOT be paid any remuneration for 
the time you spend with us for this interview / study. The information provided by you will be kept in 
strict confidence. Under no circumstances shall we reveal the identity of the respondent or their families 
to anyone. The information that we collect shall be used for approved research purposes only. You will 
be informed about any significant new findings - including adverse events, if any, – whether directly 
related to you or to other participants of this study, developed during the course of this research which 
may relate to your willingness to continue participation. 
 
 
Consent: The above information regarding the study, has been read by me/ read to me, and has been 
explained to me by the investigator/s. Having understood the same, I hereby give my consent to them 
to interview me. I am affixing my signature / left thumb impression to indicate my consent and 
willingness to participate in this study (i.e., willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
 
Signature of the Interviewer with date:      Witness: 
 
 
 
 
´ôÒ¾ø ÀÊÅõ 
§¾¾¢ :   
 
þÃ. Óò¾Á¢ú Å£½ ¬¸¢Â ¿¡ý, â. º¡. §¸¡. ÁÕòÐÅì ¸øæÃ¢Â¢ý, ÁÕó¾¢Âø Ð¨ÈÂ¢ý 
¸£ú, §ÁüÀÊôÒ ÀÊòÐì ¦¸¡ñÎ þÕì¸¢§Èý, ¿¡ý “¿¡ûÀð¼ «Æüº¢ìÌõ ¨¾Ã¡öÎ ÍÃôÒì Ì¨È 
ÁüÚõ ÍÃôÀ¢ º¢¸¢î¨ºìÌõ þ¨¼Â¢Ä¡É ¯È×” ±ýÈ ¾¨ÄôÀ¢ý ¸£ú ¬ö× §Áü¦¸¡ûÇ ¯û§Çý. 
 
±ý ¬ö× ÅÆ¢¸¡ðÊ: §ÀÃ¡º¢Ã¢¨Â. ÁÕ. ¸¢. ÒÅ§ÉŠÅÃ¢, ¾¨Ä¨Á, ÁÕó¾¢Âø Ð¨È 
 
¬ö× §Áü¦¸¡ûÅ¾ü¸¡É «ÊôÀ¨¼:  
¨¾Ã¡öÎ ÍÃôÒìÌ¨È §¿¡ö ÁüÚõ þÃò¾ìÌÆ¡ö «¨¼ôÒ §¿¡ö þó¾¢Â÷¸Ç¢¨¼§Â 
ÀÃÅÄ¡¸ ¯ûÇÐ. þ¨Å þÃñÊüÌõ þ¨¼§Â þÕìÌõ ¯È× ÁüÚõ ÍÃôÀ¢ º¢¸¢î¨ºÂ¢É¡ø ÅÕõ 
Á¡üÈí¸û ÀüÈ¢Â ¬Ã¡öîº¢ Á¢¸ì Ì¨È×. þ¾ý «ÊôÀ¨¼Â¢ø þó¾ ¬Ã¡öîº¢ 
§Áü¦¸¡ûÇôÀÎ¸¢ÈÐ. 
 
¬öÅ¢ý §¿¡ì¸õ: 
¨¾Ã¡öÎ Ì¨È ÁüÚõ ÍÃôÀ¢ º¢¸¢î¨º ¦ÀÚõ §¿¡Â¡Ç¢¸ÙìÌ À¡Š§À¡Ä¢ô§ÀŠ ÁüÚõ 
«Êô§À¡ÉìÊý «Ç× ¸ñ¼È¢Å§¾ ¬öÅ¢ý §¿¡ì¸õ. 
 
¬öÅ¢ø ÀíÌ ¦ÀÚõ ¿À÷¸Ç¢ý ±ñ½¢ì¨¸: 60 
¬ö× §Áü¦¸¡ûÙõ þ¼õ: â. º¡. §¸¡. ÁÕòÐÅÁ¨É, §¸¡ÂõÒòà÷. 
¬öÅ¢ý ÀÄý¸û: 
±ÉÐ ¬öÅ¢É¡ø ÅÕõ ¸Äí¸Ç¢ø ¨¾Ã¡öÎ Ì¨È ¯ûÇ §¿¡Â¡Ç¢¸ÙìÌ À¡Š§À¡Ä¢ô§ÀŠ 
ÁüÚõ «Êô§À¡ÉìÊý «Ç× ãÄõ þÃò¾ìÌÆ¡ö «¨¼ôÒ §¿¡ö ÅÕÅ¨¾ Óý§À ¸ñ¼È¢óÐ 
¾ÎòÐ Å¢¼ Å¡öôÒÇÐ. 
¬öÅ¢É¡ø ²üÀÎõ «¦ºÇ¸Ã¢Âí¸û / Àì¸ Å¢¨Ç×¸û: ±Ð×Á¢ø¨Ä 
þó¾ ¬öÅ¢ø ¸¢¨¼ìÌõ ¾¸Åø¸û 5 ÅÕ¼í¸û À¡Ð¸¡ì¸ôÀÎõ. þ¨Å §¾¨ÅôÀð¼¡ø 
§ÅÚ ¬öÅ¢üÌõ ÀÂýÀÎò¾ôÀ¼Ä¡õ. ±ó¾ ¿¢¨ÄÂ¢Öõ ¯í¸¨Çô ÀüÈ¢Â ¾¸Åø¸û Â¡ÕìÌõ 
¦¾Ã¢Å¢ì¸ôÀ¼Á¡ð¼¡Ð. «¨Å þÃ¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ. 
þó¾ ¬öÅ¢ø Àí§¸ü¸ ´ôÒì¦¸¡ûÅ¾¡ø ±ó¾ Å¢¾Á¡É ÀÄÛõ ¯í¸ÙìÌ ¸¢¨¼ì¸¡Ð. 
±ó¾ §¿Ãò¾¢ø §ÅñÎÁ¡É¡Öõ ¬öÅ¢Ä¢ÕóÐ Å¢Ä¸¢ì¦¸¡ûÙõ ¯Ã¢¨Á ¯í¸ÙìÌ ¯ñÎ. 
¬öÅ¢Ä¢ÕóÐ Å¢Ä¸¢ì¦¸¡ûÅ¾¡ø ¯í¸ÙìÌ «Ç¢ì¸ôÀÎõ º¢¸¢î¨ºÂ¢ø ±ó¾ Å¢¾ Á¡üÈÓõ 
þÕì¸¡Ð. 
þó¾ ¬Ã¡öîº¢ì¸¡¸ ¯í¸Ç¢¼õ º¢Ä §¸ûÅ¢¸û §¸ð¸ôÀÎõ / º¢Ä þÃò¾ Á¡¾¢Ã¢¸û «øÄÐ 
¾¢Í Á¡¾¢Ã¢¸û ±Îì¸ôÀÎõ. 
 
§ÁÖõ, þó¾ ¬öÅ¢ø ÀíÌ ¦¸¡ûÅÐ ¯í¸û ¦º¡ó¾ Å¢ÕôÀõ. þ¾¢ø ±ó¾ Å¢¾ì ¸ð¼¡ÂÓõ 
þø¨Ä. ¿£í¸û Å¢ÕôÀô Àð¼¡ø, þó¾ ¬öÅ¢ý ÓÊ×¸û ¯í¸ÙìÌò ¦¾Ã¢Âô ÀÎò¾ôÀÎõ.  
 
¬öÅ¡ÇÃ¢ý ¨¸¦Â¡ôÀõ : 
§¾¾¢ :  
 
¬ö×ìÌðÀÎÀÅÃ¢ý ´ôÒ¾ø: 
¿¡ý þó¾ ¬Ã¡öîº¢Â¢ý §¿¡ì¸õ ÁüÚõ «¾ý ÀÂýÀ¡ðÊ¨Éô ÀüÈ¢ ¦¾Ç¢Å¡¸×õ, 
Å¢Çì¸Á¡¸×õ ¦¾Ã¢ÂôÀÎò¾ô ÀðÎû§Çý. þó¾ ¬Ã¡öîº¢Â¢ø ÀíÌ ¦¸¡ûÇ×õ, þó¾ 
¬Ã¡öîº¢Â¢ý ÁÕòÐÅ Ã£¾¢Â¡É ÌÈ¢ôÒ¸¨Ç ÅÕõ ¸¡Äò¾¢Öõ ¯À§Â¡¸ôÀÎò¾¢ì ¦¸¡ûÇ×õ ÓØ 
ÁÉÐ¼ý ºõÁ¾¢ì¸¢§Èý. 
 
¬ö×ìÌðÀÎÀÅÃ¢ý ¦ÀÂ÷, Ó¸ÅÃ¢ : 
 
¨¸¦Â¡ôÀõ : 
§¾¾¢ : 
 
¬öÅ¡ÇÃ¢ý ¦¾¡¨Ä§Àº¢ ±ñ: 9787130111 
ÁÉ¢¾ ¦¿È¢Ó¨Èì ÌØ «ÖÅÄ¸ò¾¢ý ¦¾¡¨Ä§Àº¢ ±ñ: 0422 2570170 Extn.: 5818 
 ANNEXURE 9.4 
 
 
 
 
ANNEXURE 9.5 
 
Patients Age Sex BMI Duration Low or high dose Family 
history 
TSH 
(mIU/L) 
PLA2G2A 
(ng/ml) 
Adiponectin 
(pg/ml) 
1 47 M 29.75 new new nil 32.85 14.368 3.72 
2 27 F 20.83 2 yrs low yes 6.59 8.474 3.53 
3 30 F 24.44 5yrs low nil 15.8 7 0.362 
4 43 F 24 2yrs high yes 100 8.842 4.971 
5 42 F 28.95 9yrs new yes 8.63 6.263 5.317 
6 48 F 23.73 10yrs low nil 37.23 12.158 3.93 
7 23 F 19.53 3 yrs high yes 37.65 7 2.667 
8 34 M 26.98 5yrs high nil 12.11 11.421 3.93 
9 61 F 32.42 13yrs low nil 5.48 8.105 5.432 
10 35 F 36.4 5yrs low yes 52.02 11.421 7.967 
11 30 F 30.38 new new nil 5.94 1.474 3.358 
12 36 F 27.55 10yrs high nil 6.43 6.263 3.358 
13 45 F 20.26 new new nil 9.59 11.789 5.169 
14 25 F 17.18 5yrs high yes 100 9.211 1.745 
15 29 F 21.64 1yr low yes 6.98 8.842 0.938 
16 50 F 23.72 9months low nil 7.87 7.368 4.165 
17 21 F 28.88 1yr low nil 10.03 8.474 0.593 
18 22 F 27.99 new new nil 6.12 2.579 2.897 
19 28 F 21.9 new new nil 7.58 8.842 5.547 
20 29 F 24.6 new new nil 6.29 7.737 5.169 
21 45 F 26.7 new new nil 8.42 9.211 4.626 
22 32 F 37.39 new new nil 74.99 8.474 5.169 
23 23 F 27.05 new new nil 5.84 7.368 7.045 
24 22 F 25.63 3yrs high yes 23.69 1.842 4.51 
25 26 F 15.81 new new nil 8.23 2.579 7.045 
26 35 F 28.87 8yrs low nil 23.14 12.158 3.128 
27 30 F 35.15 4months low nil 31.19 8.474 2.782 
28 24 F 20.02 4months low nil 7.55 8.105 6.123 
29 37 F 34.22 8yrs low yes 5.3 7 2.551 
30 53 F 22.68 12yrs new no 6.07 2.947 6.93 
31 42 F 34.77 new new nil 6.25 1.474 3.704 
32 37 F 25.39 1month new yes 5 13.632 2.206 
33 40 F 24.97 6yrs high yes 21 9.579 1.745 
34 22 F 36 1week low yes 11.42 8.842 5.547 
35 52 F 28 10yrs high yes 28.52 7.737 3.819 
36 18 F 23.31 1yr high yes 21.09 1.474 3.704 
37 22 F 15.15 6months new yes 8.97 17.316 8.428 
38 24 F 21.23 1yr high nil 5.35 7.737 6.584 
39 50 F 30.04 4 months low nil 8.36 5.158 2.091 
40 25 F 22.86 4months low nil 5.1 14.737 2.091 
41 39 F 26.5 14yrs low nil 36.41 12.158 2.667 
42 28 F 15.73 2 yrs high nil 23.49 1.474 9.695 
43 39 F 26.62 15yrs low yes 9.97 19.526 2.782 
44 25 F 16.61 2 yrs low nil 6.5 2.947 2.206 
45 19 F 22.43 2 yrs low yes 11.96 9.579 7.391 
46 33 F 26.44 5yrs high yes 8.22 8.842 0.132 
47 49 F 28.84 10yrs high yes 4 12.895 1.169 
48 43 F 25.72 8yrs low yes 9.06 1.474 4.049 
49 18 F 15.87 new new nil 5.21 8.105 4.28 
50 71 F 24.56 5yrs low yes 5 5.895 8.658 
51 46 F 23.73 2yrs low nil 5.2 12.158 4.049 
52 35 F 27.89 5yrs low yes 10.98 7.368 2.667 
53 34 F 20.96 10yrs low nil 5.21 7 5.663 
54 51 F 26.99 2yrs low nil 2.6 2.211 1.86 
55 37 F 25 6yrs low yes 3 9.211 4.049 
56 26 F 23.63 3yrs low yes 44.06 6.263 4.049 
57 31 F 22.89 5months low nil 3.7 16.579 3.934 
58 70 F 22.04 8yrs low yes 42.1 5.158 1.169 
59 46 F 27.01 12yrs low yes 10.61 7.737 1.975 
60 55 F 29.34 6yrs low nil 0.005 11.789 3.243 
 
 
